<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel>
    <title>Thomas Barnard - Seeking Alpha</title>
    <description>'Thomas Barnard' Tag RSS Syndication from SeekingAlpha.com</description>
    <author>
      <name>SeekingAlpha.com</name>
    </author>
    <link>http://seekingalpha.com/author/thomas-barnard</link>
    <item>
      <title>Big Pharma:  Where's the Risk Management?</title>
      <link>http://seekingalpha.com/article/147364-big-pharma-where-s-the-risk-management?source=feed</link>
      <guid isPermaLink="false">147364</guid>
      <content>
        <![CDATA[<p>Novo Nordisk (<a href='http://seekingalpha.com/symbol/novo' title='More opinion and analysis of NOVO'>NOVO</a>) wrote down $280 million for its investment in inhaled insulin in January of 2008, but this is dwarfed by Pfizer&rsquo;s (<a href='http://seekingalpha.com/symbol/pfe' title='More opinion and analysis of PFE'>PFE</a>) write off in November of 2007 of $2.8 billion for its investment in Exubera, its entry into the inhaled insulin market. By March of 2008, Lilly (<a href='http://seekingalpha.com/symbol/lly' title='More opinion and analysis of LLY'>LLY</a>) also gave up the ghost, and wrote down its efforts in the area.</p>  <div> </div> <div><p>Interestingly, in 2000 Lilly had taken shown an interest in insulin taken in through the buccal tissues inside the cheek with a $1 million investment in Generex (<a href='http://seekingalpha.com/symbol/gnbt' title='More opinion and analysis of GNBT'>GNBT</a>). More about this delivery system later.</p></div>]]>
      </content>
      <pubDate>Tue, 07 Jul 2009 08:20:59 -0400</pubDate>
      <author>Thomas Barnard</author>
      <description>
        <![CDATA[<strong><a href='http://www.barnardobserver.com/'>Thomas Barnard</a> submits:</strong><p>Novo Nordisk (<a href='http://seekingalpha.com/symbol/novo' title='More opinion and analysis of NOVO'>NOVO</a>) wrote down $280 million for its investment in inhaled insulin in January of 2008, but this is dwarfed by Pfizer&rsquo;s (<a href='http://seekingalpha.com/symbol/pfe' title='More opinion and analysis of PFE'>PFE</a>) write off in November of 2007 of $2.8 billion for its investment in Exubera, its entry into the inhaled insulin market. By March of 2008, Lilly (<a href='http://seekingalpha.com/symbol/lly' title='More opinion and analysis of LLY'>LLY</a>) also gave up the ghost, and wrote down its efforts in the area.</p>  <div> </div> <div><p>Interestingly, in 2000 Lilly had taken shown an interest in insulin taken in through the buccal tissues inside the cheek with a $1 million investment in Generex (<a href='http://seekingalpha.com/symbol/gnbt' title='More opinion and analysis of GNBT'>GNBT</a>). More about this delivery system later.</p></div><br/><a href='http://seekingalpha.com/article/147364-big-pharma-where-s-the-risk-management?source=feed'>Complete Story &raquo;</a>]]>
      </description>
      <category type="symbol" link="http://seekingalpha.com/symbol/gnbt">GNBT</category>
      <category type="symbol" link="http://seekingalpha.com/symbol/lly">LLY</category>
      <category type="symbol" link="http://seekingalpha.com/symbol/nvo">NVO</category>
      <category type="symbol" link="http://seekingalpha.com/symbol/pfe">PFE</category>
      <category type="author" link="http://seekingalpha.com/author/thomas-barnard">Thomas Barnard</category>
    </item>
    <item>
      <title>This Is Where Sisyphus Starts Huffing and Puffing</title>
      <link>http://seekingalpha.com/article/140670-this-is-where-sisyphus-starts-huffing-and-puffing?source=feed</link>
      <guid isPermaLink="false">140670</guid>
      <content>
        <![CDATA[<p>Using data from Robert Schiller&rsquo;s <a href="http://www.econ.yale.edu/~shiller/data.htm">spreadsheet</a>, it looks like the S&amp;P 500 has a current PE of 15.<span>  </span>The average PE for the 128 years Schiller has records is on the order of 16.<span>   </span>So, for the momentum players we are below average, and that&rsquo;s bullish.</p>    <p>Here&rsquo;s my problem: it&rsquo;s been 25 years since the PE for the S&amp;P 500 has been in the single digits, and the important thing to remember about an average is sometimes the PE will go above the average and sometimes below, but usually there is regression to the mean.<span>  </span></p>]]>
      </content>
      <pubDate>Mon, 01 Jun 2009 10:41:05 -0400</pubDate>
      <author>Thomas Barnard</author>
      <description>
        <![CDATA[<strong><a href='http://www.barnardobserver.com/'>Thomas Barnard</a> submits:</strong><p>Using data from Robert Schiller&rsquo;s <a href="http://www.econ.yale.edu/~shiller/data.htm">spreadsheet</a>, it looks like the S&amp;P 500 has a current PE of 15.<span>  </span>The average PE for the 128 years Schiller has records is on the order of 16.<span>   </span>So, for the momentum players we are below average, and that&rsquo;s bullish.</p>    <p>Here&rsquo;s my problem: it&rsquo;s been 25 years since the PE for the S&amp;P 500 has been in the single digits, and the important thing to remember about an average is sometimes the PE will go above the average and sometimes below, but usually there is regression to the mean.<span>  </span></p><br/><a href='http://seekingalpha.com/article/140670-this-is-where-sisyphus-starts-huffing-and-puffing?source=feed'>Complete Story &raquo;</a>]]>
      </description>
      <category type="symbol" link="http://seekingalpha.com/symbol/aoa">AOA</category>
      <category type="symbol" link="http://seekingalpha.com/symbol/aok">AOK</category>
      <category type="symbol" link="http://seekingalpha.com/symbol/aom">AOM</category>
      <category type="symbol" link="http://seekingalpha.com/symbol/aor">AOR</category>
      <category type="symbol" link="http://seekingalpha.com/symbol/sds">SDS</category>
      <category type="symbol" link="http://seekingalpha.com/symbol/spx">SPX</category>
      <category type="symbol" link="http://seekingalpha.com/symbol/sso">SSO</category>
      <category type="author" link="http://seekingalpha.com/author/thomas-barnard">Thomas Barnard</category>
    </item>
  </channel>
</rss>
